Document 0847
 DOCN  M95A0847
 TI    The ratio of AIDS to non-AIDS Medicaid medical costs from 1992 to 2000.
 DT    9510
 AU    Kotzan JA; McMillan CA; Pharmacy Care Administration, University of
       Georgia, Athens, USA.
 SO    Clin Ther. 1995 Mar-Apr;17(2):320-9. Unique Identifier : AIDSLINE
       MED/95339383
 AB    Our research objective was to calculate and forecast the monthly
       increase in medical and prescription costs for Medicaid patients with
       acquired immunodeficiency syndrome (AIDS) and compare these values with
       costs for non-AIDS patients. A retrospective analysis of AIDS patients
       and a control group of Georgia Medicaid beneficiaries was conducted
       between January 1, 1988, and December 31, 1991. AIDS patients were
       defined using the Keyes algorithm of combinations of International
       Classification of Diseases, 9th Revision, Clinical Modification codes.
       The AIDS patient group was matched demographically to a group of
       non-AIDS patients. Data were adjusted to account for eligibility status,
       and the ratio of AIDS costs to non-AIDS costs was modeled with an
       econometric time series procedure. A total of 1966 AIDS patients were
       identified from 900,000 Medicaid recipients in the study period; 58.0%
       were male and 59.8% were black. Age was bimodal at < or = 1 year and 33
       years. The best fit for the medical cost ratios produced a significant
       regression coefficient of .37. The initial ratio of AIDS to non-AIDS
       forecast was 4.25 in January 1992. The January 2000 forecast of this
       ratio increased to 42.56. This increase equates to an additional
       $8510.19 per AIDS patient-month for January 2000 in 1991 dollars. The
       outpatient prescription ratio for AIDS versus non-AIDS patients was not
       predictable. However, the greatest observed discrepancies were
       attributed to the expense for antihemophilia products. Overall, the most
       important finding was the accelerating medical costs for treating AIDS
       patients compared with costs for treating non-AIDS patients. These
       results may, in part, reflect additional costs for treating intravenous
       drug users and pediatric AIDS patients.
 DE    Acquired Immunodeficiency Syndrome/*ECONOMICS/THERAPY  Adult
       Comparative Study  *Cost of Illness  Fees, Pharmaceutical/*TRENDS
       Female  *Forecasting  Human  Infant  Infant, Newborn  Male
       Medicaid/*ECONOMICS  Support, Non-U.S. Gov't  United States  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).